Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

DiA Imaging Analysis Raises $5 Million to Scale AI-Powered Ultrasound Imaging Analysis Technology

Connecticut Innovations,Incorporated
Posted on: 07 Aug 18
DiA Imaging Analysis Raises $5 Million to Scale AI-Powered Ultrasound Imaging Analysis Technology Funding Round, Led by Connecticut Innovations, Will Allow Company to More Deeply Penetrate and Expand Ultrasound Imaging Analysis Tools into Target Markets.

PR Newswire

BE'ER SHEVA, Israel, Aug. 7, 2018

BE'ER SHEVA, Israel, Aug. 7, 2018 /PRNewswire-PRWeb/ -- DiA Imaging Analysis, an artificial intelligence medical imaging analysis startup, today announced that the company has closed a $5 million funding round led by Connecticut Innovations with participation from Defta Healthcare, existing investors and a government grant from the Israel Innovation Authority.

DiA plans to use the new capital to continue penetrating the market with its FDA/CE-approved automated tools while at the same time expanding its portfolio and building support teams for its activities in the United States, Europe and Asia.

DiA's automated AI and imaging analysis technology delivers accurate and reproducible imaging analysis of ultrasound images. The company's tools utilize advanced, proprietary pattern recognition and machine learning algorithms that can improve monitoring of patient conditions, offering physicians easy-to-use tools to support their decisions and improve patient outcomes.

DiA is collaborating with market leaders including GE Healthcare, Neusoft Medical System, Google Cloud and others to implement its FDA/CE-approved automated tools within ultrasound devices, healthcare IT systems and cloud platforms. The company has reference cites in leading US medical centers, including Yale, Mount Sinai, RUSH, USF and UCSD. DiA's Scientific Advisory Board is supported by world-leading physicians specializing in cardiology and primary care ultrasound.

"The medical imaging analysis market is expanding rapidly, while the need for automation is increasing," said DiA co-founder and CEO Hila Goldman Aslan. "DiA's innovative technology and market traction will continue bringing cutting-edge solutions to the market to improve patient care. I welcome our new investors and thank them, along with our existing investors, for their support in our vision to lead the ultrasound imaging analysis market."

"The team at DiA Imaging Analysis continues to make great strides in bringing to market their groundbreaking ultrasound analysis technology, powered by artificial intelligence, that improves patient care," said Peter Longo, Senior Managing Director for Investments at Connecticut Innovations. "We are excited about their prospects for success as we continue to support their commercialization activities."

About DiA Imaging Analysis
DiA Imaging Analysis Ltd. is a medical imaging analysis software company providing fully automated, implementable tools that enable quick, objective and accurate ultrasound analysis, with the first product line in echocardiography. The company's FDA- and CE-cleared cognitive image processing tools are based on advanced pattern recognition and machine learning algorithms that automatically imitate the way the human eye identifies borders and motion, producing accurate and reliable data for the use of physicians. Headquartered in Israel, the company was founded by Hila Goldman Aslan (CEO), Michal Yaacobi (VP R&D) and Arnon Toussia-Cohen (VP BD).

For additional information, please visit http://www.dia-analysis.com.

 

SOURCE Connecticut Innovations, Incorporated

PR Newswire
www.prnewswire.com

Last updated on: 07/08/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.